By incorporating manufacturability and regulatory considerations early in research, BTI innovates novel biological products that include antibodies, exosomes, gene therapy, cell therapy, and alternative proteins for food.
BTI leverages expertise in both mammalian and microbial expression systems to optimise yield and quality of biological products by vector and cellular engineering. Cell lines and technologies are available for licensing.
BTI employs state-of-the-art systems and algorithms to optimise culture media composition and feed strategies. Serum-free, xeno-free, protein-free, and chemically defined formulations have been developed in-house or with industry partners.
A comprehensive suite of technologies from cell clarification, filtration, chromatography, virus inactivation, to sterilisation enables BTI to adopt industry standards for scalable isolation and purification of biological products.
BTI’s infrastructure permits scale-up and integration of unit operations up to 50 litres in pre-cGMP settings. Both single- and multi-use modalities are available for preclinical process development. BTI actively develops scaled-down models for selected unit operations.
BTI performs deep characterisation of bioprocesses and products to improve yield, quality and safety. Novel sensors and virtual models are being developed to better understand, monitor, and control the bioprocess.
From groundbreaking discoveries to cutting-edge research, our researchers are empowering the next generation of female science, technology, engineering and mathematics (STEM) leaders. Get inspired by our #WomeninSTEM